Breaking Finance News

ValuEngine upgraded Spark Therapeutics Inc (NASDAQ:ONCE) to Hold in a report released today.

Yesterday Spark Therapeutics Inc (NASDAQ:ONCE) traded 0.66% higher at $62.84. The company’s 50-day moving average is $82.07 and its 200-day moving average is $73.77. The last closing price is down 11.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 1,016,361 shares of the stock traded hands, up from an average trading volume of 486,840

ValuEngine has upgraded Spark Therapeutics Inc (NASDAQ:ONCE) to Hold in a report released on 06/20/2017.

See Chart Below

Spark Therapeutics Inc (NASDAQ:ONCE)

Spark Therapeutics Inc has a 52 week low of $35.07 and a 52 week high of $85.26 The company’s market cap is currently $0.

A total of 9 analysts have released a report on Spark Therapeutics Inc. zero analysts rating the company a strong buy, five analysts rating the company a buy, three analysts rating the company a hold, zero analysts rating the company a underperform, and finally one analyst rating the company a sell with a 12-month price target of $58.44.

More About Spark Therapeutics Inc (NASDAQ:ONCE)

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.